Golimumab Compliance In Long-Term Arthritis Treatment STUDY BACKGROUND Biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are the cornerstones in treating inflammatory arthritides such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA). Tumor necrosis factor-alpha (TNFα) inhibitors, including adalimumab, infliximab and golimumab are the most commonly prescribed
Tag: treatment retention
